Eidos Therapeutics to Present at Two Upcoming Investor Conferences
February 21 2019 - 8:00AM
Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX) today announced that
management will present at two upcoming investor conferences.
- SVB Leerink Global Healthcare Conference The
company will present on Thursday, February 28,
2019 at 11:00 a.m. ET. The conference will be held in New
York, NY.
- Barclays Global Healthcare Conference The
company will present on Tuesday, March 12,
2019 at 10:15 a.m. ET. The conference will be held
in Miami, FL.
Live audio webcasts of the presentations can be accessed through
the Events & Presentations section of the company's website at
ir.eidostx.com. Archived replays of the webcasts will be available
on the company's website for 90 days following the live
presentations.
About Eidos Therapeutics
Eidos Therapeutics is a clinical stage biopharmaceutical company
focused on addressing the large and growing unmet need in diseases
caused by transthyretin (TTR) amyloidosis (ATTR). Eidos is
developing AG10, a potentially disease-modifying therapy for the
treatment of ATTR. For more information, please visit
www.eidostx.com.
About transthyretin amyloidosis (ATTR)
ATTR represents a significant unmet need of a comparatively
large patient population in the context of rare genetic diseases
with an inadequate current standard of care. There are three
distinct diseases that comprise the ATTR family: wild-type ATTR
cardiomyopathy (ATTRwt-CM), mutant ATTR cardiomyopathy (ATTRm-CM),
and ATTR polyneuropathy (ATTR-PN). The worldwide prevalence of each
disease is approximately 400,000 patients, 40,000 patients and
10,000 patients, respectively.
All three forms of ATTR are progressive and fatal. For patients
with ATTRwt-CM and ATTRm-CM, symptoms usually manifest later in
life (age 50+), with median survival of three to five years from
diagnosis. ATTR-PN either presents in a patient's early 30s or
later (age 50+), and results in a median life expectancy of five to
ten years from diagnosis. Progression of all forms of ATTR causes
significant morbidity, impacts productivity and quality of life,
and creates a significant economic burden due to the costs
associated with progressively greater patient needs for supportive
care.
About AG10
AG10 is an investigational, orally-administered small molecule
designed to potently stabilize tetrameric transthyretin, or TTR,
thereby halting at its outset the series of molecular events that
give rise to amyloidosis, or ATTR. In a Phase 2 clinical trial in
ATTR-CM patients, AG10 was generally well tolerated, demonstrated
>90% TTR average stabilization at day 28, and increased serum
TTR concentrations, a prognostic indicator of survival in ATTR-CM
in a dose-dependent manner. AG10 is currently being studied in an
open-label extension of a Phase 2 clinical trial in patients with
ATTR cardiomyopathy.
AG10 was designed to mimic a naturally-occurring variant of the
TTR gene (T119M) that is considered a rescue mutation because
co-inheritance has been shown to prevent ATTR in individuals also
inheriting a pathogenic, or disease-causing, mutation in the TTR
gene. To our knowledge, AG10 is the only TTR stabilizer in
development that has been observed to mimic the “super-stabilizing”
properties of this rescue mutation
Media Contact:
Carolyn Hawley, Canale Communications, (619) 849-5382,
carolyn@canalecomm.com
Investor Contact:
Alex Gray, Burns McClellan, (212) 213-0006,
agray@burnsmc.com
Eidos Therapeutics (NASDAQ:EIDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Eidos Therapeutics (NASDAQ:EIDX)
Historical Stock Chart
From Apr 2023 to Apr 2024